Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Hempdocon Aug 07, 2020 11:49pm
215 Views
Post# 31382040

RE:RE:RE:RE:Wow!

RE:RE:RE:RE:Wow!

Well said Eoganacht & StevenB....

It would be nice to know how bladder volume has been generally calculated in other trials utilizing intravesical chemotherapy, & did TLT follow the standard...?  If not, I would think an explanation is warranted as to why & who...  We have a miracle compound that is underachieving not because of error by compound, but because of human error/oversight.  At least the error has been addressed (hopefully adequately) & we still have the opportunity to go 12 for 12 CR at 1 yr if "all" are allowed to undergo a second treatment.  

As for the definition of a clinical trial, I guess I hold it to a much higher standard.  A trial of this magnitude (everything riding on "one" indication) backed by such a high level of scientific/medical expertise in an FDA IND-approved Ph 2 should "not" be compromised like it has imo.  I don't care how big the company is.  A failure/weakness due to an inherent weakness of a drug/treatment, low accrual, or other factors out of our control is acceptable.  A failure in screening protocol (avoidable human error) at this stage is much harder to swallow.  Botch me once, shame on science.  Botch me twice, shame on the scientist.

As for the pandemic, there is NO EXCUSE to not enroll new patients from a safety/healthcare standpoint, especially in Canada!!  A handful of deaths/day by Covid & we're still having this discussion...So, when Canada has a "surge" to a "dozen" deaths/day, what happens then?  This trial being set back potentially a full year is an outrage & major insult to anyone with intelligence.  Someone has got us by the ba!!s & won't let go...wonder who that may be.  Elective procedures are full-steam ahead (even in much of the US) & a high-risk cancer patient has to wait...gimme a break said the wise man.

No more excuses...get this trial up & running!  Just calling it like it is...Have to thank the holy man we have TLD 1433, Sherri & an RP without the fee.  Now time for another shot of whiskey...ugh.

 

Bullboard Posts